Table 1.

The ratio of the expression of miR-200c, ZEB1, ZEB2, TIMP2, FBLN5, and VEGFA in each leiomyoma (L) over its own paired myometrium (M) from untreated group (n=43) representing to follicular (Follicular; n=12) and luteal (Luteal; n=19) phases of the menstrual cycle and women experiencing AUB (n=12) and those who received GNRHa (n=9), Depo (n=17), and those taking OCPs (n=7). The ratio represents the number of leiomyoma over its own paired myometrium expressing elevated (up) or lower (down) levels of miR-200c and its target genes at 1.3-fold change cutoff with percentage shown in parentheses for each group and total number of paired tissues analyzed (n value)

L/M	Follicular	Luteal	AUB	GNRH	Depo	OCP
miR-200c
Up	3/12 (0.25)	6/19 (0.316)	1/12 (0.083)	0	6/17 (0.353)	3/7 (0.429)
Down	8/12 (0.667)	11/19 (0.579)	10/12 (0.833)	7/9 (0.778)	8/17 (0.471)	2/7 (0.286)
n value	12	19	12	9	17	7
ZEB1
Up	2/11 (0.182)	3/19 (0.158)	5/12 (0.417)	1/9 (0.111)	3/14 (0.214)	0
Down	4/11 (0.364)	6/19 (0.316)	3/12 (0.25)	7/9 (0.778)	4/14 (0.286)	4/5 (0.8)
n value	11	19	12	9	14	5
ZEB2
Up	1/9 (0.111)	3/19 (0.158)	1/12 (0.083)	2/9 (0.222)	2/14 (0.143)	0
Down	7/9 (0.778)	9/19 (0.474)	10/12 (0.833)	5/9 (0.556)	8/14 (0.571)	4/4 (1)
n value	9	19	12	9	14	4
TIMP2
Up	1/9 (0.111)	1/16 (0.063)	3/12 (0.25)	0	3/11 (0.273)	0
Down	5/9 (0.556)	8/16 (0.5)	4/12 (0.333)	4/6 (0.667)	2/11 (0.182)	3/3 (1)
n value	9	16	12	6	11	3
FBLN5
Up	1/7 (0.143)	1/16 (0.063)	3/12 (0.25)	0	3/11 (0.273)	0
Down	2/7 (0.286)	7/16 (0.438)	8/12 (0.667)	5/6 (0.833)	6/11 (0.545)	3/3 (1)
n value	7	16	12	6	11	3
VEGFA
Up	5/9 (0.556)	3/16 (0.188)	8/12 (0.667)	1/6 (0.167)	0	2/3 (0.667)
Down	2/9 (0.222)	6/16 (0.375)	3/12 (0.25)	4/6 (0.667)	5/11 (0.455)	1/3 (0.333)
n value	9	16	12	6	11	3